800-TEMPLE-MED Schedule Appointment
SEARCH TEMPLE HEALTH

Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA)

view all Clinical Trials

Overview

The primary objective of the study is to determine the effect of seralutinib on improving exercise capacity in subjects with WHO Group 1 PAH who are FC II or III. The secondary objective for this trial is to determine time to clinical worsening.

Clinical Trial Information

Protocol

IRB#: 31200

Phase

3

Condition(s)

Pulmonary Arterial Hypertension (PAH)

Investigator

Paul Forfia, MD

Coordinator

Lillian Finlaw, RN
215-707-3898

Visit clinicaltrials.gov for full description.

Contact

For more information about this trial or to inquire about eligibility, call 215-707-3898.

Full Title

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Oral Inhalation of Seralutinib for the Treatment of Pulmonary Arterial Hypertension (PAH)

Related Clinical Trials

A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension (ARTISAN)

IRB#: 30634
  • Conditions: Pulmonary Arterial Hypertension (PAH)
  • Investigator: Ahmed Sadek, MD
  • Coordinator: Liz Westburg (215-707-3898)
View Details

Assessment of Combined CCM and ICD Device in HFrEF (INTEGRA-D)

IRB#: 30636
  • Conditions: Heart Failure
  • Investigator: Edmond Cronin, MD, CCDS, FHRS
  • Coordinator: Liz Westburg (215-707-3898)
View Details

Assessment of CCM in HF With Higher Ejection Fraction (AIM HIGHer)

IRB#: 29417
  • Conditions: Heart Failure
  • Investigator: Eman Hamad, MD
  • Coordinator: Kriti Rawat (215-707-3898)
View Details